<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01490931</url>
  </required_header>
  <id_info>
    <org_study_id>SPRIX IMPLANT 001</org_study_id>
    <nct_id>NCT01490931</nct_id>
  </id_info>
  <brief_title>Intranasal Ketorolac for Postsurgical Pain in Dental Implant Patients</brief_title>
  <official_title>Single-dose and Multi-dose Open-label Pilot Trial of the Analgesic Efficacy and Tolerability of Intranasal Ketorolac Tromethamine (SPRIX®) in Dental Implant Surgery Patients With Postoperative Pain.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hersh, Elliot V., DMD, MS, PhD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hersh, Elliot V., DMD, MS, PhD</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The surgical placement of dental implants is presently a common procedure performed by oral
      surgeons, periodontists, and general dentists. The surgery can be performed under local
      anesthesia and involves the incision of soft tissue to expose the underlying bone,
      preparation of the implant site using a specialized surgical drill, and.screwing the implant
      into bone using a specialized headpiece. Dental implant patients experience postoperative
      pain yet there are no studies in the literature which have evaluated the efficacy of
      analgesics in this patient population. The current pilot study will evaluate the analgesic
      effects and tolerability of a recently FDA-approved analgesic formulation of intranasal
      ketorolac (SPRIX®) in 25 patients who have 1 - 3 dental implants surgically placed. Patients
      will self administer the ketorolac nasal spray (one spray in each nostril, 31.5 mg total
      dose) when their postoperative pain reaches at least a moderate severity. Pain intensity and
      pain relief scores will then be recorded every 20 minutes for the first hour, at 1.5 and 2
      hours and then hourly through 6 hours on a validated analgesic diary. Side effects will be
      recorded when and if they occur. Patients will then transition to a multi-dose phase where
      they will be allowed to dose with ketorolac as indicated in the package insert (up to 4 times
      per day for 5 days). Patients will record the time of each dose, a daily assessment of
      overall efficacy and side effects, and the use of any rescue medication (acetaminophen 650
      mg) on a take home diary.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES

        1. Overall Objectives The purpose of this pilot study will be to evaluate the analgesic
           efficacy and tolerability of intranasal ketorolac employed at doses and dosing intervals
           stated in the package insert in patients experiencing moderate to severe pain following
           dental implant surgery. This open label study should provide data that will allow us to
           estimate sample size for a future placebo-controlled trial in the dental implant surgery
           population.

        2. Primary Outcome Variable(s) To determine if intranasal ketorolac significantly reduces
           pain intensity scores when compared to baseline pain intensity as measured by the area
           under the 6-hour pain intensity difference (SPID-6).

        3. Secondary Outcome Variable(s) To determine the median onset of first perceptible,
           confirmed first perceptible, and meaningful pain relief of intranasal ketorolac in
           dental implant surgery patients.

      To compare mean post-dose pain intensity scores at each time-point with the baseline pain
      intensity score during the initial 6-hour evaluation period.

      To calculate the area under the 6-hour pain relief time action curve (TOTPAR-6) for
      intranasal ketorolac.

      To calculate the percentage of subjects who reach a level of at least moderate pain by
      achieving a score of at least 40 mm on a 100 mm visual analog scale within 5 hours after the
      completion of surgery.

      To determine the mean number of days of analgesic dosing in dental implant surgery patients
      when employing intranasal ketorolac as their pain medication.

      To determine the number of patients taking rescue medication (acetaminophen 650 mg) and the
      mean number of rescue medication doses taken in dental implant surgery patients when
      employing intranasal ketorolac as their pain medication.

      To determine the overall tolerability of intranasal ketorolac in dental implant surgery
      patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of Pain Intensity Scores at 20 Minutes With the Baseline Pain Intensity Score During the Initial 6-hour Evaluation Period.</measure>
    <time_frame>20 minutes post dose</time_frame>
    <description>Pain intensity scores will be recorded by patient employing a standard 100 mm visual analog scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of Pain Intensity Scores at 40 Minutes With the Baseline Pain Intensity Score During the Initial 6-hour Evaluation Period.</measure>
    <time_frame>40 minutes post dose</time_frame>
    <description>VAS pain intensity score at 40 minutes post-dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of Pain Intensity Scores at 60 Minutes With the Baseline Pain Intensity Score During the Initial 6-hour Evaluation Period</measure>
    <time_frame>60 minutes post dose</time_frame>
    <description>VAS pain intensity score 60 minutes after dosing.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of Pain Intensity Scores at 90 Minutes With the Baseline Pain Intensity Score During the Initial 6-hour Evaluation Period</measure>
    <time_frame>90 minutes post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of Pain Intensity Scores at 2 Hours With the Baseline Pain Intensity Score During the Initial 6-hour Evaluation Period</measure>
    <time_frame>2 Hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of Pain Intensity Scores at 3 Hours With the Baseline Pain Intensity Score During the Initial 6-hour Evaluation Period</measure>
    <time_frame>3 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of Pain Intensity Scores at 4 Hours With the Baseline Pain Intensity Score During the Initial 6-hour Evaluation Period</measure>
    <time_frame>4 Hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of Pain Intensity Scores at 5 Hours With the Baseline Pain Intensity Score During the Initial 6-hour Evaluation Period</measure>
    <time_frame>5 Hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of Pain Intensity Scores at 6 Hours With the Baseline Pain Intensity Score During the Initial 6-hour Evaluation Period</measure>
    <time_frame>6 Hours post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Median Onset of First Perceptible Pain Relief of Intranasal Ketorolac in Dental Implant Surgery Patients</measure>
    <time_frame>Censored at 6 hours</time_frame>
    <description>Data will be obtained employing the well-described double stop watch technique</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Who Reach a Level of at Least Moderate Pain by Achieving a Score of at Least 40 mm on a 100 mm Visual Analog Scale Within 5 Hours After the Completion of Surgery.</measure>
    <time_frame>Up to 5 hours after last suture is placed</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Most Frequent Number of Days of Analgesic Dosing in Dental Implant Surgery Patients When Employing Intranasal Ketorolac as Their Pain Medication.</measure>
    <time_frame>Up to 5 days</time_frame>
    <description>Self explanatory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Onset of Meaningful Pain Relief</measure>
    <time_frame>At time of depressing meaningful relief stopwatch up to 6 hours.</time_frame>
    <description>Measure obtained using recognized double-stop watch technique. Patient is asked to depress the second stop watch when pain relief is meaningful to them. Each patient decides what meaningful relief is for them.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Acute Pain</condition>
  <arm_group>
    <arm_group_label>Ketorolac nasal spray 31.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Recommended dose according to package insert in 18 - 64 year olds for moderate to moderately severe pain.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketorolac Nasal Spray</intervention_name>
    <description>15.75 mg nasal spray delivery to each nostril no more than every six hours</description>
    <arm_group_label>Ketorolac nasal spray 31.5 mg</arm_group_label>
    <other_name>SPRIX</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Key Inclusion Criteria

          1. Male or female between 18 and 64 years of age.

          2. Must sign informed consent prior to initiation of any study procedures. The subject
             must be able to understand and agree to cooperate with study requirements.

          3. BMI between 19 and 29 kg/m2.

          4. Must require the surgical placement of 1 - 3 dental implants that are being placed in
             a one or two stage non-immediately loaded surgical procedure employing 2% lidocaine
             and/or 4% articaine with epinephrine and/or 3% mepivacaine plain for local anesthesia.

          5. Females of child-bearing potential must have a negative urine pregnancy test at
             screening and immediately prior to the initiation of dental implant surgery and must
             have been using adequate means of birth control (abstinence, oral contraceptive
             steroids, intrauterine device (IUD), etc.) for at least one month prior to study entry
             and during the study.

          6. In the opinion of the investigators the subject can safely tolerate ketorolac and
             acetaminophen.

        Exclusion Criteria:

        Key Exclusion Criteria

          1. Require the placement of more than 3 implants or require extensive bone grafting in
             addition to implant placement.

          2. Need to administer anxiolytic/sedation drugs during surgery other than nitrous
             oxide/oxygen.

          3. Need to administer the long acting local anesthetic bupivacaine with 1:200,000
             epinephrine.

          4. Implant(s) that are going to be immediately loaded on the day of surgery

          5. Females that are pregnant or breast feeding

          6. Allergies or hypersensitivity (aspirin sensitive asthma) to ketorolac, aspirin,
             ibuprofen, other NSAIDs, or acetaminophen.

          7. History of gastrointestinal ulcers and/or bleeding.

          8. On warfarin, dicumarol, clopidogrel or any other anticoagulant or antiplatelet therapy
             other than low dose (81 mg - 325 mg) aspirin.

          9. Clinically significant kidney or liver disease where the intake of NSAIDs or
             acetaminophen would put the subject at undo risk.

         10. Blood pressure greater than 160/95 at the time of screening or immediately before
             surgery.

         11. Inflammation of the nasal mucosa or upper respiratory tract infection

         12. Have ingested any analgesic agent within 48 hours of surgery.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elliot V Hersh, DMD, MS, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Univeristy of Pennsylvania School of Dental Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pennsylvania School of Dental Medicine</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-6030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.drugs.com/sprix.html</url>
    <description>SPRIX prescribing information</description>
  </link>
  <link>
    <url>http://www.aaoms.org/dental_implants.php</url>
    <description>Overview of dental implants from American Association of Oral and Maxillofacial Surgeons</description>
  </link>
  <reference>
    <citation>Al-Khabbaz AK, Griffin TJ, Al-Shammari KF. Assessment of pain associated with the surgical placement of dental implants. J Periodontol. 2007 Feb;78(2):239-46.</citation>
    <PMID>17274712</PMID>
  </reference>
  <reference>
    <citation>Hersh EV, Levin LM, Adamson D, Christensen S, Kiersch TA, Noveck R, Watson G 2nd, Lyon JA. Dose-ranging analgesic study of Prosorb diclofenac potassium in postsurgical dental pain. Clin Ther. 2004 Aug;26(8):1215-27.</citation>
    <PMID>15476903</PMID>
  </reference>
  <results_reference>
    <citation>Bockow R, Korostoff J, Pinto A, Hutcheson M, Secreto SA, Bodner L, Hersh EV. Characterization and treatment of postsurgical dental implant pain employing intranasal ketorolac. Compend Contin Educ Dent. 2013 Sep;34(8):570-6.</citation>
    <PMID>24564610</PMID>
  </results_reference>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 11, 2011</study_first_submitted>
  <study_first_submitted_qc>December 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2011</study_first_posted>
  <results_first_submitted>February 24, 2014</results_first_submitted>
  <results_first_submitted_qc>April 11, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 9, 2014</results_first_posted>
  <last_update_submitted>April 11, 2014</last_update_submitted>
  <last_update_submitted_qc>April 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acute pain</keyword>
  <keyword>dental pain</keyword>
  <keyword>intranasal ketorolac</keyword>
  <keyword>dental implant surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Ketorolac Tromethamine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Consecutive patients in PENN periodontal clinic or faculty practice requiring 1 to 3 dental implants employing lidocaine with epinephrine for anesthesia without significant bone augmentation</recruitment_details>
      <pre_assignment_details>Subjects not experiencing moderate pain (at least 40 mm on the pain intensity VAS and moderate or severe pain on the 4-point categorical scale) within 4 hours of surgery were not dosed with ketorolac. Of the 28 enrolled subjects, 25 (89%) achieved at least moderate pain and were dosed.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Ketorolac Nasal Spray 31.5 mg (SPRIX)</title>
          <description>Recommended dose according to package insert in 18 - 64 year olds for moderate to moderately severe pain.
Ketorolac Tromethamine Nasal Spray: 15.75 mg nasal spray delivery to each nostril no more than every six hours</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Pilot Study. No power analysis performed.</population>
      <group_list>
        <group group_id="B1">
          <title>Ketorolac Nasal Spray 31.5 mg (SPRIX)</title>
          <description>Recommended dose according to package insert in 18 - 64 year olds for moderate to moderately severe pain.
Ketorolac Tromethamine Nasal Spray: 15.75 mg nasal spray delivery to each nostril no more than every six hours</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>pain intensity on 100 mm visual analog scale (VAS). 0=No pain 100=worst possible pain</title>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.4" spread="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>The Median Onset of First Perceptible Pain Relief of Intranasal Ketorolac in Dental Implant Surgery Patients</title>
        <description>Data will be obtained employing the well-described double stop watch technique</description>
        <time_frame>Censored at 6 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketorolac Nasal Spray 31.5 mg (SPRIX)</title>
            <description>Recommended dose according to package insert in 18 - 64 year olds for moderate to moderately severe pain.
Ketorolac Tromethamine Nasal Spray: 15.75 mg nasal spray delivery to each nostril no more than every six hours</description>
          </group>
        </group_list>
        <measure>
          <title>The Median Onset of First Perceptible Pain Relief of Intranasal Ketorolac in Dental Implant Surgery Patients</title>
          <description>Data will be obtained employing the well-described double stop watch technique</description>
          <units>seconds</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86" lower_limit="64" upper_limit="172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Comparison of Pain Intensity Scores at 20 Minutes With the Baseline Pain Intensity Score During the Initial 6-hour Evaluation Period.</title>
        <description>Pain intensity scores will be recorded by patient employing a standard 100 mm visual analog scale</description>
        <time_frame>20 minutes post dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketorolac Nasal Spray 31.5 mg (SPRIX)</title>
            <description>Recommended dose according to package insert in 18 - 64 year olds for moderate to moderately severe pain.
Ketorolac Tromethamine Nasal Spray: 15.75 mg nasal spray delivery to each nostril no more than every six hours</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Pain Intensity Scores at 20 Minutes With the Baseline Pain Intensity Score During the Initial 6-hour Evaluation Period.</title>
          <description>Pain intensity scores will be recorded by patient employing a standard 100 mm visual analog scale</description>
          <units>millimeters</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Changes in pain intensity on the VAS were statistically compared to baseline pain utilizing paired t tests with Bonferroni corrections for multiple comparisons. The median onsets of first perceptible and meaningful relief (with 95% confidence intervals) were calculated and then used to construct Kaplan-Meier Curves of the distribution of pain relief times.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P value adjusted with Bonferroni corrections for multiple comparisons</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Who Reach a Level of at Least Moderate Pain by Achieving a Score of at Least 40 mm on a 100 mm Visual Analog Scale Within 5 Hours After the Completion of Surgery.</title>
        <time_frame>Up to 5 hours after last suture is placed</time_frame>
        <population>All subjects (regardless of pain intensity) receiving one to three dental implants</population>
        <group_list>
          <group group_id="O1">
            <title>Ketorolac Nasal Spray 31.5 mg (SPRIX)</title>
            <description>Recommended dose according to package insert in 18 - 64 year olds for moderate to moderately severe pain.
Ketorolac Tromethamine Nasal Spray: 15.75 mg nasal spray delivery to each nostril no more than every six hours</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Who Reach a Level of at Least Moderate Pain by Achieving a Score of at Least 40 mm on a 100 mm Visual Analog Scale Within 5 Hours After the Completion of Surgery.</title>
          <population>All subjects (regardless of pain intensity) receiving one to three dental implants</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Most Frequent Number of Days of Analgesic Dosing in Dental Implant Surgery Patients When Employing Intranasal Ketorolac as Their Pain Medication.</title>
        <description>Self explanatory</description>
        <time_frame>Up to 5 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketorolac Nasal Spray 31.5 mg (SPRIX)</title>
            <description>Recommended dose according to package insert in 18 - 64 year olds for moderate to moderately severe pain.
Ketorolac Tromethamine Nasal Spray: 15.75 mg nasal spray delivery to each nostril no more than every six hours</description>
          </group>
        </group_list>
        <measure>
          <title>Most Frequent Number of Days of Analgesic Dosing in Dental Implant Surgery Patients When Employing Intranasal Ketorolac as Their Pain Medication.</title>
          <description>Self explanatory</description>
          <units>days</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Onset of Meaningful Pain Relief</title>
        <description>Measure obtained using recognized double-stop watch technique. Patient is asked to depress the second stop watch when pain relief is meaningful to them. Each patient decides what meaningful relief is for them.</description>
        <time_frame>At time of depressing meaningful relief stopwatch up to 6 hours.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketorolac Nasal Spray 31.5 mg (SPRIX)</title>
            <description>Recommended dose according to package insert in 18 - 64 year olds for moderate to moderately severe pain.
Ketorolac Tromethamine Nasal Spray: 15.75 mg nasal spray delivery to each nostril no more than every six hours</description>
          </group>
        </group_list>
        <measure>
          <title>Median Onset of Meaningful Pain Relief</title>
          <description>Measure obtained using recognized double-stop watch technique. Patient is asked to depress the second stop watch when pain relief is meaningful to them. Each patient decides what meaningful relief is for them.</description>
          <units>seconds</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="172" lower_limit="132" upper_limit="735"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Comparison of Pain Intensity Scores at 40 Minutes With the Baseline Pain Intensity Score During the Initial 6-hour Evaluation Period.</title>
        <description>VAS pain intensity score at 40 minutes post-dose</description>
        <time_frame>40 minutes post dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketorolac Nasal Spray 31.5 mg (SPRIX)</title>
            <description>Recommended dose according to package insert in 18 - 64 year olds for moderate to moderately severe pain.
Ketorolac Tromethamine Nasal Spray: 15.75 mg nasal spray delivery to each nostril no more than every six hours</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Pain Intensity Scores at 40 Minutes With the Baseline Pain Intensity Score During the Initial 6-hour Evaluation Period.</title>
          <description>VAS pain intensity score at 40 minutes post-dose</description>
          <units>millimeters</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.1" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Changes in pain intensity on the VAS were statistically compared to baseline pain utilizing paired t tests with Bonferroni corrections for multiple comparisons. The median onsets of first perceptible and meaningful relief (with 95% confidence intervals) were calculated and then used to construct Kaplan-Meier Curves of the distribution of pain relief times.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Comparison of Pain Intensity Scores at 60 Minutes With the Baseline Pain Intensity Score During the Initial 6-hour Evaluation Period</title>
        <description>VAS pain intensity score 60 minutes after dosing.</description>
        <time_frame>60 minutes post dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketorolac Nasal Spray 31.5 mg (SPRIX)</title>
            <description>Recommended dose according to package insert in 18 - 64 year olds for moderate to moderately severe pain.
Ketorolac Tromethamine Nasal Spray: 15.75 mg nasal spray delivery to each nostril no more than every six hours</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Pain Intensity Scores at 60 Minutes With the Baseline Pain Intensity Score During the Initial 6-hour Evaluation Period</title>
          <description>VAS pain intensity score 60 minutes after dosing.</description>
          <units>millimeters</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.6" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Changes in pain intensity on the VAS were statistically compared to baseline pain utilizing paired t tests with Bonferroni corrections for multiple comparisons. The median onsets of first perceptible and meaningful relief (with 95% confidence intervals) were calculated and then used to construct Kaplan-Meier Curves of the distribution of pain relief times.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Comparison of Pain Intensity Scores at 90 Minutes With the Baseline Pain Intensity Score During the Initial 6-hour Evaluation Period</title>
        <time_frame>90 minutes post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketorolac Nasal Spray 31.5 mg (SPRIX)</title>
            <description>Recommended dose according to package insert in 18 - 64 year olds for moderate to moderately severe pain.
Ketorolac Tromethamine Nasal Spray: 15.75 mg nasal spray delivery to each nostril no more than every six hours</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Pain Intensity Scores at 90 Minutes With the Baseline Pain Intensity Score During the Initial 6-hour Evaluation Period</title>
          <units>millimeters</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.6" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Changes in pain intensity on the VAS were statistically compared to baseline pain utilizing paired t tests with Bonferroni corrections for multiple comparisons. The median onsets of first perceptible and meaningful relief (with 95% confidence intervals) were calculated and then used to construct Kaplan-Meier Curves of the distribution of pain relief times.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Comparison of Pain Intensity Scores at 2 Hours With the Baseline Pain Intensity Score During the Initial 6-hour Evaluation Period</title>
        <time_frame>2 Hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketorolac Nasal Spray 31.5 mg (SPRIX)</title>
            <description>Recommended dose according to package insert in 18 - 64 year olds for moderate to moderately severe pain.
Ketorolac Tromethamine Nasal Spray: 15.75 mg nasal spray delivery to each nostril no more than every six hours</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Pain Intensity Scores at 2 Hours With the Baseline Pain Intensity Score During the Initial 6-hour Evaluation Period</title>
          <units>millimeters</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Changes in pain intensity on the VAS were statistically compared to baseline pain utilizing paired t tests with Bonferroni corrections for multiple comparisons. The median onsets of first perceptible and meaningful relief (with 95% confidence intervals) were calculated and then used to construct Kaplan-Meier Curves of the distribution of pain relief times.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Comparison of Pain Intensity Scores at 3 Hours With the Baseline Pain Intensity Score During the Initial 6-hour Evaluation Period</title>
        <time_frame>3 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketorolac Nasal Spray 31.5 mg (SPRIX)</title>
            <description>Recommended dose according to package insert in 18 - 64 year olds for moderate to moderately severe pain.
Ketorolac Tromethamine Nasal Spray: 15.75 mg nasal spray delivery to each nostril no more than every six hours</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Pain Intensity Scores at 3 Hours With the Baseline Pain Intensity Score During the Initial 6-hour Evaluation Period</title>
          <units>millimeters</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.6" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Changes in pain intensity on the VAS were statistically compared to baseline pain utilizing paired t tests with Bonferroni corrections for multiple comparisons. The median onsets of first perceptible and meaningful relief (with 95% confidence intervals) were calculated and then used to construct Kaplan-Meier Curves of the distribution of pain relief times.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0001</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Comparison of Pain Intensity Scores at 4 Hours With the Baseline Pain Intensity Score During the Initial 6-hour Evaluation Period</title>
        <time_frame>4 Hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketorolac Nasal Spray 31.5 mg (SPRIX)</title>
            <description>Recommended dose according to package insert in 18 - 64 year olds for moderate to moderately severe pain.
Ketorolac Tromethamine Nasal Spray: 15.75 mg nasal spray delivery to each nostril no more than every six hours</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Pain Intensity Scores at 4 Hours With the Baseline Pain Intensity Score During the Initial 6-hour Evaluation Period</title>
          <units>millimeters</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Changes in pain intensity on the VAS were statistically compared to baseline pain utilizing paired t tests with Bonferroni corrections for multiple comparisons. The median onsets of first perceptible and meaningful relief (with 95% confidence intervals) were calculated and then used to construct Kaplan-Meier Curves of the distribution of pain relief times.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Comparison of Pain Intensity Scores at 5 Hours With the Baseline Pain Intensity Score During the Initial 6-hour Evaluation Period</title>
        <time_frame>5 Hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketorolac Nasal Spray 31.5 mg (SPRIX)</title>
            <description>Recommended dose according to package insert in 18 - 64 year olds for moderate to moderately severe pain.
Ketorolac Tromethamine Nasal Spray: 15.75 mg nasal spray delivery to each nostril no more than every six hours</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Pain Intensity Scores at 5 Hours With the Baseline Pain Intensity Score During the Initial 6-hour Evaluation Period</title>
          <units>millimeters</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.2" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Changes in pain intensity on the VAS were statistically compared to baseline pain utilizing paired t tests with Bonferroni corrections for multiple comparisons. The median onsets of first perceptible and meaningful relief (with 95% confidence intervals) were calculated and then used to construct Kaplan-Meier Curves of the distribution of pain relief times.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Comparison of Pain Intensity Scores at 6 Hours With the Baseline Pain Intensity Score During the Initial 6-hour Evaluation Period</title>
        <time_frame>6 Hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketorolac Nasal Spray 31.5 mg (SPRIX)</title>
            <description>Recommended dose according to package insert in 18 - 64 year olds for moderate to moderately severe pain.
Ketorolac Tromethamine Nasal Spray: 15.75 mg nasal spray delivery to each nostril no more than every six hours</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Pain Intensity Scores at 6 Hours With the Baseline Pain Intensity Score During the Initial 6-hour Evaluation Period</title>
          <units>millimeters</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.8" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Changes in pain intensity on the VAS were statistically compared to baseline pain utilizing paired t tests with Bonferroni corrections for multiple comparisons. The median onsets of first perceptible and meaningful relief (with 95% confidence intervals) were calculated and then used to construct Kaplan-Meier Curves of the distribution of pain relief times.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>5 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ketorolac Nasal Spray 31.5 mg (SPRIX)</title>
          <description>Recommended dose according to package insert in 18 - 64 year olds for moderate to moderately severe pain.
Ketorolac Tromethamine Nasal Spray: 15.75 mg nasal spray delivery to each nostril no more than every six hours</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ears popping sensation</sub_title>
                <description>Transient immediately after dosing</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Watery eyes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <description>3 of 25 (12%) reported headache sometime during 5 day evaluation period</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal burning or stinging</sub_title>
                <description>Transient nasal burning on dosing in 9/25 (36%) of subjects</description>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Throat burning</sub_title>
                <description>Transient throat burning on dosing 3/25 subjects (12%)</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Sneezing</sub_title>
                <description>Sneezing on dosing 2/25 (8%)</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Difficulty breathing sensation</sub_title>
                <description>Transient difficulty breathing sensation immediately after dosing</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Runny nose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Perspiring</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The major weakness of this study was its open-label design and lack of a placebo control and an active comparator drug. The study was also not powered to determine differences between the sites of implant placement and the number of implants placed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Elliot V Hersh DMD, MS, PhD Professor of Pharmacology</name_or_title>
      <organization>Univeristy of Pennsylvania School of Dental Medicine</organization>
      <phone>215-898-9686</phone>
      <email>evhersh@pobox.upenn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

